Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa.

[1]  Shira Doron,et al.  SYMPOSIUM ON ANTIMICROBIAL THERAPYAntimicrobial Stewardship , 2011 .

[2]  N. Goel,et al.  Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. , 2011, The Journal of antimicrobial chemotherapy.

[3]  R. Weinstein,et al.  Recommendations For Metrics For Multidrug-Resistant Organisms In Healthcare Settings: SHEA/HICPAC Position Paper , 2008, Infection Control & Hospital Epidemiology.

[4]  T. Kirikae,et al.  Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. , 2008, The Journal of antimicrobial chemotherapy.

[5]  J. Mcgowan.  Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, The American journal of medicine.

[6]  N. Ohmagari,et al.  Risk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer , 2005, Cancer.

[7]  H. Sun,et al.  Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. , 2004, The Journal of hospital infection.

[8]  R. Regal,et al.  The Effect of an Antimicrobial Restriction Program on Pseudomonas aeruginosa Resistance to β‐Lactams in a Large Teaching Hospital , 2003, Pharmacotherapy.

[9]  H. Giamarellou.  Prescribing guidelines for severe Pseudomonas infections. , 2002, The Journal of antimicrobial chemotherapy.

[10]  Y. Tabe,et al.  Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.